After huge mega-round, CStone poaches Goldman's Richard Yeh as CFO; Both Hooper and Harper exit Amgen's revolving door
→ Weeks after closing its star-studded $260 million Series B round, CStone Pharmaceuticals has poached Goldman Sachs director Richard Yeh to manage all of that money and more. As CFO, Yeh’s duties will cover corporate financial strategies, financial reporting, risk management, funding, and IPO. Given CStone’s ambitious plan to go after frontrunners in the PD-L1 field (like Bristol-Myers Squibb’s Yervoy, Merck’s Keytruda and Novartis’ Mekinist) with its own Phase I drug candidate, Yeh is expected to contribute insight gleaned from his years leading research on both Chinese and US biotech industries. The immuno-oncology player has inked a couple of licensing pacts with US biotechs, including with Agios on ivosidenib, its newly approved treatment for advanced acute myeloid leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.